EluNIR-PERL Ridaforolimus Eluting Coronary Stent System
Medinol, Ltd. · Decision date Aug 7, 2025
What did the FDA decide?
FDA records P170008/S059 as a supplement to PMA P170008, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Aug 7, 2025.
FDA approval order statement
a change to the leak testing procedure
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Aug 7, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P170008/S059
- Regulatory pathway
- PMA supplement
- Applicant
- Medinol, Ltd.
- Product code
- NIQ
- Decision code
- OK30
- Decision date
- Aug 7, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Medinol, Ltd.
- Product code
- NIQ
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P170008/S059 received
Application receipt date recorded by FDA.
P170008/S059 · FDA decision
30-Day Notice
P170008/S060 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
P170008/S056 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
P170008/S061 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
P170008/S062 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
P170008/S064 · Related supplement
EluNIR Ridaforolimus Eluting Coronary Stent System
Timeline entries are records held by MedtechLedger for P170008. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170008
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medinol, Ltd. | PMA supplement | Aug 15, 2025 | FDA | |
| Medinol, Ltd. | PMA supplement | Oct 2, 2025 | FDA | |
| Medinol, Ltd. | PMA supplement | Feb 4, 2026 | FDA | |
| Medinol, Ltd. | PMA supplement | Mar 26, 2026 | FDA | |
| Medinol, Ltd. | PMA supplement | Aug 6, 2026 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA | |
ORSIRO Sirolimus Eluting Coronary Stent SystemP170030/S066 | Biotronik AG | PMA supplement | Sep 24, 2026 | FDA |
| Abbott Vascular | PMA supplement | Aug 28, 2026 | FDA | |
| BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 21, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medinol, Ltd.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Kiryat Atidim, Bldg. 8, P.O.B. 58165, Tel Aviv, 6158101
Sources and methodology
- Original FDA record: P170008/S059
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records





